Brady Family Wealth LLC Buys 222 Shares of Zoetis Inc. (NYSE:ZTS)

Brady Family Wealth LLC grew its stake in Zoetis Inc. (NYSE:ZTS) by 18.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,416 shares of the company’s stock after buying an additional 222 shares during the period. Brady Family Wealth LLC’s holdings in Zoetis were worth $231,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Darwin Wealth Management LLC acquired a new stake in Zoetis in the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis in the third quarter worth $33,000. Dunhill Financial LLC boosted its holdings in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the period. Finally, Quarry LP grew its stake in Zoetis by 273.2% in the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.7 %

ZTS opened at $167.23 on Thursday. The firm has a market cap of $75.45 billion, a price-to-earnings ratio of 31.43, a PEG ratio of 2.51 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm’s 50-day simple moving average is $171.31 and its 200-day simple moving average is $180.16. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the company posted $1.36 earnings per share. Zoetis’s quarterly revenue was up 11.6% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio is presently 32.52%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ZTS shares. Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.